Juno Therapeutics | Cell Tribune: Cell and Gene Therapy News and Research

Immunotherapy

Juno Therapeutics’ and Celgene Corporation’s Investigational Drug JCAR017 Granted Breakthrough Therapy...

Cell Tribune - December 21, 2016 0

- Early results recently announced with JCAR017 in non-Hodgkin lymphoma and pediatric acute lymphoblastic leukemia -- Pivotal DLBCL trial expected to begin in 2017 SEATTLE &...

Tag: Juno Therapeutics

Juno Therapeutics’ and Celgene Corporation’s Investigational Drug JCAR017 Granted Breakthrough Therapy...

EVEN MORE NEWS

U.S. Food and Drug Administration Places Clinical Hold On Cellectis MELANI-01...

New Antimicrobial Resistance (AMR) Action Fund steps in to save collapsing...

Sonoma Biotherapeutics launches with $40 million in Series A funding to...

POPULAR CATEGORY